Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Alnylam, Alcon, and More


Title: siRNA Compositions and Methods for Potently Inhibiting Viral Infection

Patent Number: 8,664,188

Filed: Dec. 11, 2009

Lead Inventor: Bojian Zheng, Xiangxue Group

Title: RNA Interference in Skin Indications

Patent Number: 8,664,189

Filed: Sept. 22, 2009

Lead Inventor: Anastasia Khvorova, RXi Pharmaceuticals

Title: Mutator Activity Induced by microRNA-155 Links Inflammation and Cancer

Patent Number: 8,664,192

Filed: March 7, 2012

Inventor: Carlo Croce, Ohio State University (Microlin Bio)

Title: Compositions and Methods for Inhibiting Expression of Factor VII Gene

Patent Number: 8,664,193

Filed: Sept. 14, 2012

Lead Inventor: Antonin de Fourgerolles, Alnylam Pharmaceuticals

Title: Interfering RNA Delivery Systems and Uses Thereof

Patent Number: 8,664,375

Filed: Dec. 14, 2010

Inventor: Jon Chatterton, Alcon

Title: Use of Two microRNA [Molecules] in Lung Cancer Prognosis and Medicine Preparation

Patent Number: 8,664,191

Filed: July 9, 2009

Lead Inventor: Qimin Zhan, Chinese Academy of Medical Services

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.